Plain-English translation of NCT06064812 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called for people with advanced breast cancer that is estrogen-receptor positive and HER2-negative. The study has two main phases: the first phase tests different doses to find the safest and most effective amount, and the second phase focuses on patients whose cancer has a specific genetic change (ESR1 mutation). Researchers want to learn whether the medication is safe and whether it can slow or stop the growth of this type of breast cancer.
Many people with this type of advanced breast cancer stop responding to standard hormone therapies over time. This trial exists to explore whether this new treatment can help patients whose cancers have become resistant to older medications.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will visit the study site for screening (up to 4 weeks) to confirm you qualify, then begin taking the medication by mouth once daily for 28-day cycles. The first cycle includes a single dose followed by a 3-day observation period, then daily dosing begins. You will continue treatment for up to 2 years (or longer if your doctor believes you are benefiting and both you and the sponsor agree), with regular visits to assess how well the medication is working, check for side effects, and have blood tests. The study also includes a follow-up period after treatment ends to monitor your health.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China